Lucile Gentile

Mrs. Lucile Gentile

UMR 1078, Brest, Bretagne, France
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PCPierre Conan
Pierre Conan
ALAlice Léon
Alice Léon
MGMathilde Gourdel
Mathilde Gourdel
CRClaire Rollet
Claire Rollet
LCLoubna Chaïr
Loubna Chaïr
GFGaelle Friocourt
Gaelle Friocourt
CBS encodes a pyridoxal 5′-phosphate-dependent enzyme that catalyses the condensation of homocysteine and serine to form cystathionine. Due to its implication in some cancers and in the cognitive pathophysiology of Down syndrome, the identification of pharmacological inhibitors of this enzyme is urgently required. However, thus far, attempts to identify such molecules have only led to the identification of compounds with low potency and limited selectivity. We consequently developed an original, yeast-based screening method that identified three FDA-approved drugs of the 8-hydroxyquinoline family: clioquinol, chloroxine and nitroxoline. These molecules reduce CBS enzymatic activity in different cellular models, proving that the molecular mechanisms involved in yeast phenotypic rescue are conserved in mammalian cells. A combination of genetic and chemical biology approaches also revealed the importance of copper and zinc intracellular levels in the regulation of CBS enzymatic activity—copper promoting CBS activity and zinc inhibiting its activity. Taken together, these results indicate that our effective screening approach identified three new potent CBS inhibitors and provides new findings for the regulation of CBS activity, which is crucial to develop new therapies for CBS-related human disorders.

4 October 2024 in Marine Drugs
Verified
Journal Article
Open access
PDF file
MSMaha Sinane
Maha Sinane
CGColin Grunberger
Colin Grunberger
Lucile GentileLucile Gentile
Lucile Gentile
CMCeline Moriou
Celine Moriou
VCVictorien Chaker
Victorien Chaker
CVCécile Voisset
Cécile Voisset
The screening of 166 extracts from tropical marine organisms (invertebrates, macroalgae) and 3 cyclolipopeptides from microorganisms against yeast prions highlighted the potential of Verongiida sponges to prevent the propagation of prions. We isolated the known compounds purealidin Q (1), aplysamine-2 (2), pseudoceratinine A (3), aerophobin-2 (4), aplysamine-1 (5), and pseudoceratinine B (6) for the first time from the Wallisian sponge Suberea laboutei. We then tested compounds 1–6 and sixteen other bromotyrosine and bromophenol derivatives previously isolated from Verongiida sponges against yeast prions, demonstrating the potential of 1–3, 5, 6, aplyzanzine C (7), purealidin A (10), psammaplysenes D (11) and F (12), anomoian F (14), and N,N-dimethyldibromotyramine (15). Following biological tests on mammalian cells, we report here the identification of the hitherto unknown ability of the six bromotyrosine derivatives 1, 2, 5, 7, 11, and 14 of marine origin to reduce the spread of the PrPSc prion and the ability of compounds 1 and 2 to reduce endoplasmic reticulum stress. These two biological activities of these bromotyrosine derivatives are, to our knowledge, described here for the first time, offering a new therapeutic perspective for patients suffering from prion diseases that are presently untreatable and consequently fatal.

21 November 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Lucile GentileLucile Gentile
Lucile Gentile
ANAdeel Nasir
Adeel Nasir
LSLoane Simon
Loane Simon
ATAnaëlle Timoner
Anaëlle Timoner
APAnaïs Péron
Anaïs Péron
CVCécile Voisset
Cécile Voisset
Parkinson's disease (PD) is characterized by the pathologic aggregation of α-synuclein, which induces endoplasmic reticulum (ER) stress and activates the unfolded protein response (UPR), ultimately leading to the death of dopaminergic neurons. This study investigated whether drugs known to mitigate protein aggregation in prion disease models would attenuate the stress response and cell death in PD models. Flunarizine and ten of its structural analogues, previously identified through a drug repositioning approach to reduce the aggregation of PrPSc prion protein, were evaluated in a Chinese hamster ovary (CHO-K1) cell model. First, UPR was induced in CHO-K1 cells using tunicamycin, revealing that several of these drugs conferred protection and also reduced the expression of the UPR marker CHOP. Subsequently, we tested these anti-prion drugs in PD relevant cellular models. Neuronally-differentiated PC12 cells were employed, and all 11 drugs exhibited protective effect. Finally, human dopaminergic neurons (LUHMES cells) were exposed to 1-methyl-4-phenylpyridinium (MPP+), a compound commonly used to induce parkinsonian-like pathology. In this model, all 11 drugs demonstrated cytoprotective properties and attenuated UPR. Notably, several compounds - benzydamine, duloxetine, flunarizine, metixene and triflupromazine - protected LUHMES cells from MPP+ -induced ER stress at nanomolar concentrations. These findings provide the proof of concept that drugs selected for other indications, may be repurposed to ameliorate PD and related pathologies linked to ER stress.

9 June 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
OMOceane Martinez
Oceane Martinez
Lucile GentileLucile Gentile
Lucile Gentile
FBFloriane Bretheau
Floriane Bretheau
AYAllison Yearwood
Allison Yearwood
OAOceane Arevalo
Oceane Arevalo
AJAurelie de Rus Jacquet
Aurelie de Rus Jacquet
Parkinson’s disease (PD) is a neurodegenerative disorder traditionally characterized by dopaminergic neuron loss in the substantial nigra pars compacta , but peripheral immune dysregulation and blood-brain barrier (BBB) dysfunction have been increasingly implicated in disease etiology. However, how circulating immune cells interact with the human BBB and how these interactions are captured across experimental models remains poorly understood. In particular, human BBB models offer multiple platforms to interrogate these biological questions, with organ-on-chip approaches attracting significant interest. In this context, it is essential to determine whether model architecture influences the assessment of immune-endothelial interactions in PD, and if it may lead to fundamentally different interpretations of immune cell trafficking at the human BBB. Here, we compared peripheral blood mononuclear cells (PBMCs) from control donors or individuals with PD in human induced pluripotent stem cell (iPSC)-derived BBB models to determine how static and dynamic BBB systems influence immune cell behavior. To do so, we leveraged our brain chip platform to establish a model based on expression of the PD-associated SNCA triplication mutation. Using a two-dimensional transwell system and a three-dimensional (3D) microfluidic BBB chip, we evaluated PBMC attachment and transmigration under conditions of PBMC disease status, endothelial genotype associated with SNCA triplication, and exposure to α-synuclein (α-Syn) monomers or preformed fibrils (PFFs). PBMCs from PD donors showed increased baseline reactivity and altered endothelial interactions compared with controls. In transwell models, SNCA triplication increased PBMC attachment and selectively enhanced PD PBMC transmigration, while PFF increased attachment without affecting transmigration. In contrast, in the microfluidic BBB chip, attachment was largely unchanged by endothelial genotype or α-Syn exposure, whereas transmigration increased following α-Syn monomer pre-treatment. Together, PBMC-BBB interactions in PD appear to be shaped by immune cell status, endothelial genotype, and α-Syn exposure, but are strongly influenced by BBB model dimensionality and flow. This study underscores the importance of physiologically relevant multicellular and flow-based BBB systems and provides a human-focused framework for studying peripheral immune cell trafficking across the diseased BBB. These findings also emphasize that biological insights into BBB function are inherently shaped by the experimental model used, underscoring the need for complementary human BBB platforms.

8 April 2026
Verified
Thesis
Closed access
Lucile GentileLucile Gentile
Lucile Gentile
La maladie de Parkinson (MP) est, comme les maladies à prions, une maladie du repliement des protéines dont la caractéristique moléculaire majeure est l‘agrégation pathologique de la protéine α-Synucléine. Cette agrégation induit un stress du réticulum endoplasmique (RE) qui mène à la mort des neurones dopaminergiques, ce qui provoque les symptômes moteurs caractéristiques de la maladie. Il n’existe actuellement aucun traitement curatif de la MP. L’identification de molécules capables de réduire cette agrégation protéique pathologique et le stress du RE qui en découle est donc une piste prometteuse pour le traitement de la MP. Mon groupe de recherche a identifié trois familles de molécules (médicaments, originales et naturelles) capables de réduire l’agrégation de la protéine prion. Les caractéristiques prion-like de la MP, ainsi que la description de molécules anti-prions ayant la capacité de moduler le stress du RE telles que le guanabenz, ont conduit mon groupe à élargir son champ d’intérêt à la réduction du stress du RE dans la maladie de Parkinson. Dans ce contexte, mon projet de thèse avait pour objectif d’évaluer le potentiel thérapeutique de différentes familles de molécules anti-prions identifiées par mon groupe dans des modèles cellulaires pertinents pour la maladie de Parkinson. Mes travaux ont montré que certaines molécules anti-prions sont capables de réduire le stress du RE et permettent ainsi une cytoprotection des neurones dopaminergiques humains ayant subi un stress du RE in vitro.